Načítá se...
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide
Background: The highly vascular nature of renal carcinoma cells suggests that inhibition of angiogenesis may be beneficial in this disease. Thalidomide has been described as inhibitor of the fibroblast growth factor (FGF) and the vascular endothelial growth factor (VEGF). Therefore and in considerat...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
German Medical Science GMS Publishing House
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2716555/ https://ncbi.nlm.nih.gov/pubmed/19675744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3205/000063 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|